vs
Side-by-side financial comparison of Performance Shipping Inc. (PSHG) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $39.5M, roughly 1.8× Performance Shipping Inc.). Performance Shipping Inc. runs the higher net margin — 97.5% vs -49.0%, a 146.6% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -7.9%).
Azerbaijan Caspian Shipping Closed Joint-Stock Company is a state-owned Azerbaijani shipping company. It is also known by its Russian-derived abbreviation CASPAR.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
PSHG vs VRDN — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.5M | $70.6M |
| Net Profit | $38.5M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 93.3% | -56.7% |
| Net Margin | 97.5% | -49.0% |
| Revenue YoY | -7.9% | 81958.1% |
| Net Profit YoY | 78.1% | 54.9% |
| EPS (diluted) | $1.00 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $70.6M | ||
| Q2 25 | $39.5M | — | ||
| Q2 24 | $42.9M | — |
| Q3 25 | — | $-34.6M | ||
| Q2 25 | $38.5M | — | ||
| Q2 24 | $21.6M | — |
| Q3 25 | — | -56.7% | ||
| Q2 25 | 93.3% | — | ||
| Q2 24 | 49.1% | — |
| Q3 25 | — | -49.0% | ||
| Q2 25 | 97.5% | — | ||
| Q2 24 | 50.4% | — |
| Q3 25 | — | — | ||
| Q2 25 | $1.00 | — | ||
| Q2 24 | $0.55 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $95.8M | $490.9M |
| Total DebtLower is stronger | $43.7M | — |
| Stockholders' EquityBook value | $312.8M | $503.0M |
| Total Assets | $363.8M | $577.1M |
| Debt / EquityLower = less leverage | 0.14× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $490.9M | ||
| Q2 25 | $95.8M | — | ||
| Q2 24 | $61.7M | — |
| Q3 25 | — | — | ||
| Q2 25 | $43.7M | — | ||
| Q2 24 | $51.2M | — |
| Q3 25 | — | $503.0M | ||
| Q2 25 | $312.8M | — | ||
| Q2 24 | $254.0M | — |
| Q3 25 | — | $577.1M | ||
| Q2 25 | $363.8M | — | ||
| Q2 24 | $310.5M | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.14× | — | ||
| Q2 24 | 0.20× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.8M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 0.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-84.6M | ||
| Q2 25 | $26.8M | — | ||
| Q2 24 | $31.7M | — |
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q2 24 | 0.0% | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.70× | — | ||
| Q2 24 | 1.47× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
